We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2010 by China Medical University Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01249066
First Posted: November 29, 2010
Last Update Posted: November 29, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
China Medical University Hospital
  Purpose
AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia. Because the role of AMPK in cancers has not been fully elucidated, in this study we investigated the expression and activation of AMPK in lung adenocarcinoma (LADC) cells and tissue.

Condition
Lung Adenocarcinoma

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by China Medical University Hospital:

Estimated Enrollment: 100
Study Start Date: September 2010
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Lung cancer received lobectomy in CMUH
Criteria

Inclusion Criteria:

  • Lung cancer received operation lobectomy in CMUH

Exclusion Criteria:

  • History of uremia, other malignant disease, and liver cirrhosis
  • History of pneumonia and pulmonary tuberculosis
  • History of long period of medications.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01249066


Locations
Taiwan
Fang Hsin Yuan Recruiting
Taichung, Taiwan, 404
Contact: Hsin-Yuan Fang, MD    +886422052121 ext 1638    d93421104@ntu.edu.tw   
Sponsors and Collaborators
China Medical University Hospital
  More Information

Responsible Party: Fang Hsin-Yuan/Director, China Medical University Hospital
ClinicalTrials.gov Identifier: NCT01249066     History of Changes
Other Study ID Numbers: DMR99-IRB-096
First Submitted: November 24, 2010
First Posted: November 29, 2010
Last Update Posted: November 29, 2010
Last Verified: September 2010

Keywords provided by China Medical University Hospital:
AMP-activated protein kinase
lung adenocarcinomas
Prognosis
Observation study

Additional relevant MeSH terms:
Adenocarcinoma
Lung Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases